v3.26.1
Equity-Based Compensation - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Mar. 31, 2026
Mar. 31, 2025
Aug. 20, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Recognized stock-based compensation expense $ 18,938 $ 15,415 $ 34,945 $ 29,649      
Equity-based compensation expense 18,938 15,415 34,945 29,649      
Employee Stock Option              
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Intrinsic value of stock options exercised $ 37,200 $ 5,300 $ 70,500 $ 7,400      
Weighted-average fair value of options granted $ 59.06 $ 25.46 $ 62.3 $ 21.8      
Recognized stock-based compensation expense $ 13,531 $ 12,391 $ 25,536 $ 23,961      
Unrecognized stock-based compensation expense 110,300   $ 110,300        
Unrecognized compensation cost, recognition period     3 years 2 months 12 days        
Equity-based compensation expense 13,531 12,391 $ 25,536 23,961      
Employee Stock Option | Research and Development Arrangement [Member]              
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Recognized stock-based compensation expense 6,512 5,983 12,229 11,696      
Equity-based compensation expense 6,512 5,983 12,229 11,696      
Employee Stock Option | General and Administrative [Member]              
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Recognized stock-based compensation expense 7,019 6,408 13,307 12,265      
Equity-based compensation expense 7,019 6,408 13,307 12,265      
Restricted Stock              
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Recognized stock-based compensation expense 5,200 $ 2,800 9,000 $ 5,200      
Unrecognized stock-based compensation expense $ 56,200   $ 56,200        
Unrecognized compensation cost, recognition period     3 years 10 months 24 days        
Granted 78,725 191,300 422,967 519,100      
Equity-based compensation expense $ 5,200 $ 2,800 $ 9,000 $ 5,200      
Restricted Stock | Research and Development Arrangement [Member]              
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Recognized stock-based compensation expense 3,700 1,900 6,400 3,500      
Equity-based compensation expense 3,700 1,900 6,400 3,500      
Restricted Stock | General and Administrative [Member]              
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Recognized stock-based compensation expense 1,500 900 2,600 1,700      
Equity-based compensation expense $ 1,500 900 $ 2,600 1,700      
2020 Plan              
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Number of shares authorized for issuance under plan             4,457,370
Maximum number of shares to be issued, percentage     4.00%        
Shares remaining available for future grants 6,464,760   6,464,760        
Weighted-average fair value of options granted     $ 97.53        
Recognized stock-based compensation expense $ 200 $ 0 $ 300 $ 0      
Performance stock options vesting 60.00%   60.00%     40.00%  
Second clinical milestone vesting percentage           40.00%  
Third clinical milestone vesting percentage 15.00%   15.00%     20.00%  
Granted 0 0 95,000 88,000      
Option Indexed to Issuer's Equity, Strike Price   $ 30.17          
Performance stock options outstanding 88,000   88,000        
Equity-based compensation expense $ 200 $ 0 $ 300 $ 0      
2020 Plan | Restricted Stock              
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Granted 0 0 73,672 285,723      
2020 Plan | Performance Stock              
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Weighted-average fair value of options granted     $ 126.09        
Recognized stock-based compensation expense $ 200   $ 300        
Performance stock options vesting         60.00% 40.00%  
Second clinical milestone vesting percentage           40.00%  
Third clinical milestone vesting percentage         15.00% 20.00%  
Granted 0 0 73,672 0      
Option Indexed to Issuer's Equity, Strike Price     $ 30.17        
Equity-based compensation expense $ 200   $ 300        
2020 Plan | Minimum [Member]              
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Performance stock options range 0.00%   0.00%     0.00%  
2020 Plan | Minimum [Member] | Performance Stock              
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Performance stock options range 0.00%   0.00%   0.00%    
2020 Plan | Maximum [Member]              
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Performance stock options range 100.00%   100.00%     100.00%  
2020 Plan | Maximum [Member] | Performance Stock              
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Performance stock options range 100.00%   100.00%   100.00%    
2020 Plan | Executive Officer [Member] | Performance Stock              
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Granted   0   285,723      
2020 ESPP              
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Number of shares authorized for issuance under plan             445,653
Shares remaining available for future grants 2,716,358   2,716,358        
Share-based compensation, description     The 2020 ESPP provides that the number of shares reserved and available for issuance will automatically increase on January 1, 2021 and each January 1 thereafter through January 1, 2030, by the lesser of (i) 438,898 shares of common stock, (ii) 1% of the Company’s outstanding number of shares of common stock on the immediately preceding December 31 or (iii) such lesser number of shares of common stock as determined by the administrator of the 2020 ESPP.        
2020 ESPP | Lesser of Potential Outcome 1              
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Maximum number of shares to be issued, percentage     1.00%        
Number of additional shares authorized     438,898        
2018 Plan | Restricted Stock              
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]              
Granted     496,639